« Back
Investigating orthogonal in vitro analytical approaches to demonstrate bioequivalence (BE) of nasal suspension formulations
Poster Title: Investigating orthogonal in vitro analytical approaches to demonstrate bioequivalence (BE) of nasal suspension formulations
Submitted on 28 Aug 2018
Author(s): Gonçalo Farias, Robert Price, William Ganley, Debbie Huck-Jones, Paul Kippax & Jagdeep Shur
Affiliations: University of Bath, Malvern Instruments Limited
This poster was presented at Drug Delivery to the Lungs conference
Poster Views: 359
View poster »

Poster Information
Abstract: Nasal suspension drug products consist of API particles suspended in an aqueous system in the presence of a range of different excipients.

For suspension nasal products, the API particle size is a key critical material attribute, which will affect emitted API particle size and regional deposition of API in the nose. In addition, the particle size of the API will affect the rate of dissolution and permeability at site of deposition in the nasal epithelium and thereby systemic exposure of the API from the nose.

The paucity of validated methods for characterizing API specific drug particle size distribution (PSD) in nasal formulations has resulted in limited understanding of the relationship between API PSD, regional deposition in the nasal cavity, dissolution, and absorption of the API from the nose.

Although PSD can be readily determined by a number of methods prior to formulation into a finished product, the primary challenge has been to determine the PSD of the drug substance in the finished nasal aqueous suspension products in the presence of undissolved excipients[3]. Excipients often exhibit a broad PSD and a substantial number of excipient particles may exist in the same size range as the drug substance, thus complicating drug substance particle size determination. Morphology-directed Raman Spectroscopy (MDRS) is a promising approach for characterizing particle size of API in aqueous nasal spray suspension formulations. Morphological filters are used to allow the detection of a statistically relevant number of API particles. This approach allows the chemical identification of API in situ within complex nasal formulations which can directly benefit the BE requirements for ANDAs.
Summary: Demonstration of a combination of dissolution testing and morphologically-directed Raman spectroscopy (MDRS®) of a nasal suspension was able to discriminate between differences in API particle size in nasal suspension formulations. The approach allowed characterization of particle size distribution of the API in the formulation facilitating comparative analysis of test and reference products to help determine bioequivalence of nasal suspensions formulations using in vitro methods.References: 1. Li BV et al. AAPS J 2013, 15:875–883.
2. Doub WH, et al. Pharm. Res. 2012, 29:3122–3130.
3. Doub WH, et al. Pharm. Res. 2007, 24:934–945.
4. Rygg A, et al. Pharm. Res. 2015:1–13.
5. Mitchell J, et al. AAPS PharmSciTech 2011, 12:965–988.
6. Sharpe SA, et al. Drug Dev Ind Pharm 2003, 29:1005–1012.
7. Shur J,
Report abuse »
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters

Genetic Engineering in Male Sterility for Hybrid Variety Development
Abir Hasan Joy

VITVO: Mimicking In Vivo Complexity By The Innovative 3D Model
Olivia Candini1, Giulia Grisendi1, Elisabetta Manuela Foppiani1, Matteo Brogli1, Beatrice Aramini2, Valentina Masciale3, Carlotta Spano1, Tiziana Petrachi4, Elena Veronesi4, Pierfranco Conte5,6, Giorgio Mari1 & Massimo Dominici1,3

Helana Lutfi and Shaban Nuredini

Clinical pattern in electrophysiological variants of acute acquired polyneuropathies and their clinical outcome, a three years data
Naseebullah, Salman Mansoor, Azhar Saeed

Rare neurological deficit after electric shock A clinically diagnosed case report
Naseebullah, Salman Mansoor, Arsalan Ahmad, Shahid Shah